Aytu BioScience, Inc, a commercial-stage specialty healthcare company focused on commercialising treatments for urological conditions, announced that it has entered into a co-promotion agreement for Primsol (trimethoprim hydrochloride) oral solution with Allegis Pharmaceuticals, a commercial-stage specialty pharmaceutical company focused on the US paediatric market.
Under the agreement, Allegis will exclusively promote Primsol to paediatricians across the US. Aytu retains all other rights in the US and around the world and will continue to market the product in urologic indications.
Primsol is the only FDA-approved liquid formulation of trimethoprim, an antibiotic that is well established in current guidelines for treating uncomplicated urinary tract infections (UTIs). This differentiated product is appropriate for UTI patients that have difficulty swallowing tablets, such as the elderly, and particularly for patients that experience adverse reactions to sulfamethoxazole (sulfa). Primsol is also indicated for the treatment of acute otitis media, or middle ear infection, caused by susceptible organisms in children age six months to twelve years. Otitis media is the leading paediatric infection in the US.
Josh Disbrow, chief executive officer of Aytu BioScience, stated, “We are excited to initiate this partnership with Allegis and believe that this co-promotional agreement makes sense on multiple levels. Allegis has an experienced commercial team and a strong sales history in paediatrics–where Primsol prescribing has been consistent since the product’s launch–with a product portfolio that is complementary to Primsol. Placing the paediatric-focused marketing efforts with Allegis enables Aytu to further monetize Primsol through a long-term promotional commitment, while enabling Aytu to stay focused on our core therapeutic area of urology. We expect Allegis to regain some of the historical prescribing of paediatricians as we align our efforts to the urology market, a specialty that has historically prescribed over one-quarter of Primsol prescriptions in the US.”